| Literature DB >> 18382626 |
Michael J Russell1, Frederick L Flynt, Allyson L Harroff, Oluwole Fadare.
Abstract
Dedifferentiated liposarcomas may display a variety of "heterologous" lines of differentiation, including osseous, vascular, skeletal, and/or smooth muscular. There have been six previously reported examples of leiomyosarcomas associated with high levels of serum human chorionic gonadotropin (hCG) production, comprised of cases originating from the retroperitoneum, spermatic cord, small intestine, and uterus. This report describes the first example of a dedifferentiated liposarcoma that combined both of the aforementioned features: extensive heterologous (leiomyosarcomatous) differentiation and beta-hCG production (maximum serum levels 1046 mIU/ml, reference <5 mIU/ml). The tumor, which originated in the retroperitoneum in the region of the right kidney, was rapidly progressive and ultimately fatal within three months of its diagnosis. In addition to characteristic morphologic features, lipogenic and smooth muscle differentiation were confirmed with immunohistochemical stains for MDM2 and smooth muscle actin, respectively. The tumor also displayed diffuse immunoreactivity for beta-hCG in both primary and metastatic sites. This case further expands the clinicopathologic spectrum of lipogenic tumors.Entities:
Year: 2008 PMID: 18382626 PMCID: PMC2276869 DOI: 10.1155/2008/658090
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Figure 1Well-differentiated component of the liposarcoma, showing atypical cells with nucleomegaly and hyperchromasia scattered within mature adipocytes and intervening fibrous septae.
Figure 2The interface between the well-differentiated and dedifferentiated components.
Figure 3Cellular areas of the dedifferentiated component.
Figure 4Some areas of the dedifferentiated component were comprised of cells with varying amounts of eosinophilic cytoplasm.
Figure 5The tumor cells displayed diffuse immunoreactivity for β-hCG.
Figure 6The tumor cells displayed diffuse immunoreactivity for MDM2.